title: Updates on hepatitis C virus therapy in the direct-acting antiviral era.
abstract: OBJECTIVE
  Hepatitis C virus (HCV) is a major cause of clinical burden in the United States and worldwide, as a percentage of patients can develop complications such as cirrhosis and hepatocellular carcinoma.
  
  
  RESULTS
  Therapy for chronic HCV infection was previously interferon-based, but with the advent of direct-acting antivirals (DAAs), there has been a dramatic improvement in eradicating the virus with favourable side effect profiles.
  
  
  CONCLUSIONS
  Emerging data are demonstrating new successful agents in difficult-to-manage populations. This review is aimed to provide a brief overview of currently accepted therapy, as well providing new information on upcoming therapeutic agents available for practioners going forward.
authors.affiliation: Section of Hepatology, Rush University Medical Center, Chicago, Illinois, USA.
authors.forename: Ramakrishna
authors.initials: R
authors.lastname: Behara
authors.forename: Nancy
authors.initials: N
authors.lastname: Reau
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D060085:Coinfection; D024882:Drug Resistance, Viral; D057915:Drug Substitution; D015658:HIV Infections / Q000150:complications; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D008103:Liver Cirrhosis / Q000821:virology
chemical_list: D000998:Antiviral Agents